Fragment-based drug discovery and biological evaluation of novel cannabinol-based inhibitors of oxytosis/ferroptosis for neurological disorders
Redox Biology · 2024
DOI: 10.1016/j.redox.2024.103138 ↗Kurz gefasst
Fachartikel in der Zeitschrift Redox Biology, 2024. Verfasst von Zhibin Liang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cellular Neurobiology Laboratory, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA, 92037, United States. Elect…. Hauptthemen laut MEDLINE: Drug Discovery, Cannabinol. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, NIA NIH HHS, Glenn Foundation for Medical Research.
Abstract (Originalsprache)
The oxytosis/ferroptosis regulated cell death pathway is an emerging field of research owing to its pathophysiological relevance to a wide range of neurological disorders, including Alzheimer's and Parkinson's diseases and traumatic brain injury. Developing novel neurotherapeutics to inhibit oxytosis/ferroptosis offers exciting opportunities for the treatment of these and other neurological diseases. Previously, we discovered cannabinol (CBN) as a unique, potent inhibitor of oxytosis/ferroptosis by targeting mitochondria and modulating their function in neuronal cells. To further elucidate which key pharmacophores and chemical space are essential to the beneficial effects of CBN, we herein introduce a fragment-based drug discovery strategy in conjunction with cell-based phenotypic screens using oxytosis/ferroptosis to determine the structure-activity relationship of CBN. The resulting information led to the development of four new CBN analogs, CP1-CP4, that not only preserve the sub-micromolar potency of neuroprotection and mitochondria-modulating activities seen with CBN in neuronal cell models but also have better druglike properties. Moreover, compared to CBN, the analog CP1 shows improved in vivo efficacy in the Drosophila model of mild traumatic brain injury. Together these studies identify the key molecular scaffolds of cannabinoids that contribute to neuroprotection against oxytosis/ferroptosis. They also highlight the advantageous approach of combining in vitro cell-based assays and rapid in vivo studies using Drosophila models for evaluating new therapeutic compounds.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cellular Neurobiology Laboratory, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA, 92037, United States. Electronic address: zliang@salk.edu.
- Shiley Bioscience Center, San Diego State University, 5500 Campanile Drive, San Diego, CA, 92182, United States.
- Cellular Neurobiology Laboratory, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA, 92037, United States.
- Cellular Neurobiology Laboratory, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA, 92037, United States. Electronic address: pmaher@salk.edu.
Förderung
- NIH HHS
- NIA NIH HHS
- Glenn Foundation for Medical Research
- Shiley Foundation
- National Institute on Aging
- National Cancer Institute
Zitieren
APA
Liang, Z., Candib, A., Soriano-Castell, D., Fischer, W., Finley, K., & Maher, P. (2024). Fragment-based drug discovery and biological evaluation of novel cannabinol-based inhibitors of oxytosis/ferroptosis for neurological disorders. Redox Biology. https://doi.org/10.1016/j.redox.2024.103138
Vancouver
Liang Z, Candib A, Soriano-Castell D, Fischer W, Finley K, Maher P. Fragment-based drug discovery and biological evaluation of novel cannabinol-based inhibitors of oxytosis/ferroptosis for neurological disorders. Redox Biology. 2024. doi:10.1016/j.redox.2024.103138
BibTeX
@article{Liang2024,
author = {Liang, Zhibin and Candib, Alec and Soriano-Castell, David and Fischer, Wolfgang and Finley, Kim and Maher, Pamela},
title = {Fragment-based drug discovery and biological evaluation of novel cannabinol-based inhibitors of oxytosis/ferroptosis for neurological disorders},
journal = {Redox Biology},
year = {2024},
doi = {10.1016/j.redox.2024.103138}
}
EUVIMED